Tower Research Capital LLC TRC Sells 17,456 Shares of Danaher Corporation (DHR)
Tower Research Capital LLC TRC decreased its position in shares of Danaher Corporation (NYSE:DHR) by 89.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,020 shares of the conglomerate’s stock after selling 17,456 shares during the period. Tower Research Capital LLC TRC’s holdings in Danaher Corporation were worth $173,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in DHR. Israel Discount Bank of New York acquired a new position in shares of Danaher Corporation during the first quarter valued at $209,000. DE Burlo Group Inc. raised its position in shares of Danaher Corporation by 17.8% in the first quarter. DE Burlo Group Inc. now owns 131,450 shares of the conglomerate’s stock valued at $11,242,000 after buying an additional 19,900 shares in the last quarter. Exane Derivatives acquired a new position in shares of Danaher Corporation during the first quarter valued at $838,000. Bronfman E.L. Rothschild L.P. raised its position in shares of Danaher Corporation by 30.7% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 17,947 shares of the conglomerate’s stock valued at $1,535,000 after buying an additional 4,219 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Danaher Corporation by 52.5% in the first quarter. Toronto Dominion Bank now owns 177,994 shares of the conglomerate’s stock valued at $15,225,000 after buying an additional 61,239 shares in the last quarter. Institutional investors and hedge funds own 76.12% of the company’s stock.
Danaher Corporation (NYSE DHR) traded down 0.093% during midday trading on Tuesday, reaching $80.525. The company had a trading volume of 414,443 shares. Danaher Corporation has a 1-year low of $75.71 and a 1-year high of $88.01. The firm’s 50 day moving average is $82.75 and its 200 day moving average is $84.26. The stock has a market capitalization of $55.94 billion, a PE ratio of 25.702 and a beta of 1.03.
Danaher Corporation (NYSE:DHR) last issued its earnings results on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The company had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.50 billion. During the same period last year, the company posted $0.90 earnings per share. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities analysts anticipate that Danaher Corporation will post $3.95 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Tower Research Capital LLC TRC Sells 17,456 Shares of Danaher Corporation (DHR)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/tower-research-capital-llc-trc-sells-17456-shares-of-danaher-corporation-dhr/1490587.html.
Several brokerages recently weighed in on DHR. Royal Bank Of Canada restated a “sector perform” rating and issued a $88.00 price target (down previously from $89.00) on shares of Danaher Corporation in a research note on Friday, April 21st. BidaskClub lowered Danaher Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Zacks Investment Research lowered Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Citigroup Inc. set a $96.00 price target on Danaher Corporation and gave the company a “buy” rating in a research note on Friday, July 21st. Finally, Janney Montgomery Scott lowered Danaher Corporation from a “buy” rating to a “neutral” rating in a research note on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $91.76.
In other news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the transaction, the insider now directly owns 155,520 shares of the company’s stock, valued at approximately $12,718,425.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider William King sold 7,458 shares of the firm’s stock in a transaction that occurred on Friday, July 21st. The stock was sold at an average price of $82.97, for a total transaction of $618,790.26. Following the transaction, the insider now directly owns 18,245 shares of the company’s stock, valued at $1,513,787.65. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,623 shares of company stock valued at $3,206,426. 12.20% of the stock is currently owned by corporate insiders.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.